ライフサイエンスコーパス: varicella

1 , a neurotropic alphaherpesvirus, results in varicella.

2 in the risk of scabies, dermatophytosis and varicella.

3 r healthy individuals who are susceptible to varicella.

4 rol vaccine) for the prevention of confirmed varicella.

5 V group, and 352 (47%) in the MMR group had varicella.

6 aricella-zoster virus (VZV) infection causes varicella, after which the virus becomes latent in gangl

7 ractions in the sensory ganglia during acute varicella and demonstrate that SVV infection results in

8 [HHV3]), the human alphaherpesvirus causing varicella and herpes zoster, expresses 24 virally encode

9 virus (VZV) is a highly contagious agent of varicella and herpes zoster.

10 Zoster Virus (VZV) is the causative agent of varicella and herpes zoster.

11 Outcomes measured included varicella and HZ incidences, the incremental cost-utilit

12 Despite the lack of varicella and viral replication in either the lungs or w

13 cific genes have been associated with severe varicella and/or zoster.

14 nial nerve ganglia during primary infection (varicella), and the virus can reactivate and cause zoste

15 ertussis toxin (PT), tetanus toxoid (TT) and varicella, and immunogenicity of postchemotherapy diphth

16 ed participants' most recent stored sera for varicella antibody using whole-cell and glycoprotein enz

17 have observed a 70% reduction in the rate of varicella-associated invasive group A streptococcal infe

18 Universal childhood vaccination against varicella began in the United States as a 1-dose schedul

19 m long-term protection for the prevention of varicella by offering individual protection against all

20 fficacy endpoint was occurrence of confirmed varicella (by detection of varicella zoster virus DNA or

21 Varicella can be lethal to immunocompromised patients, b

22 Varicella cases were confirmed by detection of viral DNA

23 Varicella cases were confirmed for 37 participants in th

24 Varicella cases were moderate to severe for two particip

25 VZV causes varicella (chicken pox) and herpes zoster (shingles), wh

26 lphaherpesvirus and the etiological agent of varicella (chickenpox) and herpes zoster (HZ, shingles).

27 VZV causes varicella (chickenpox), becomes latent in ganglia, and r

28 GSK and MSD varicella-containing vaccines (VCVs) were considered.

29 dult siblings with a history of disseminated varicella, cutaneous warts, and CD4(+) T-cell lymphopeni

30 tes that reexposure to circulating wild-type varicella delays the onset of herpes zoster, predicts a

31 umococcal serotypes, tetanus, pertussis, and varicella despite previous vaccination.

32 o identify children with severe hospitalized varicella, despite availability of universal 1-dose vacc

33 strain Oka is attenuated, it can cause mild varicella, establish latency, and in rare cases, reactiv

34 ll the hallmarks of VZV infection, including varicella, immunity, latency, and reactivation.

35 age 2 years of measles, mumps, rubella, and varicella immunization may offer improved disease contro

36 modeling approaches regarding the effect of varicella immunization on HZ.

37 pathogenesis is required before further mass varicella immunization programs are set out.

38 V), of the family Alphaherpesvirinae, causes varicella in children and young adults, potentially lead

39 Similar to VZV in humans, SVV causes varicella in monkeys, establishes latency in ganglia, an

40 We assessed protection against varicella in naive children administered one dose of var

41 us, is associated with seasonal outbreaks of varicella in nonimmunized populations.

42 ct of V-MMRV and MMRV-MMRV UVV programmes on varicella incidence was comparable between both VCVs at

43 d hypogammaglobulinemia; one also had severe varicella infection.

44 ving treatment excluding doxorubicin died of varicella, metabolic seizure, and sepsis during treatmen

45 he BioPlex 2200 measles, mumps, rubella, and varicella (MMRV) IgG assay (Bio-Rad Laboratories, Hercul

46 mumps-rubella (MMR) or measles-mumps-rubella-varicella (MMRV) vaccine was assessed in children born t

47 vaccines, such as the measles-mumps-rubella-varicella (MMRV) vaccine, into immunization schedules sh

48 d virus genotyping (2 immunocompromised) had varicella (n = 2) or zoster (n = 2) due to the Oka/vacci

49 om 2007 to 2015, 327 children with confirmed varicella (n = 238) or zoster (n = 89) were enrolled.

50 aged 50 years or older who had a history of varicella or who had resided in a country with endemic v

51 While most cases of varicella or zoster are self-limited, patients with cert

52 We reviewed the literature for cases of varicella or zoster associated with primary and acquired

53 Children with varicella or zoster from 5 Paediatric Active Enhanced Di

54 s, 11 of 16 positive controls with zoster or varicella (P < .0001), 2 of 2 patients with zoster sine

55 (57.2-72.1), and against moderate to severe varicella (post hoc) was 90.7% (85.9-93.9).

56 talized varicella still occurs with a 1-dose varicella program, although predominantly in unvaccinate

57 VZV-immune RMs displayed no varicella rash and had lower SVV viral loads and earlier

58 Severe hospitalized varicella still occurs with a 1-dose varicella program,

59 Despite the burden of varicella, there is no universal varicella vaccination (

60 rus (VZV) is an alphaherpesvirus that causes varicella upon primary infection and zoster upon reactiv

61 e burden of varicella, there is no universal varicella vaccination (UVV) programme in the United King

62 Varicella vaccination can have complex direct and indire

63 The impact of varicella vaccination on the epidemiology of herpes zost

64 as declined in a step-wise pattern since the varicella vaccination program's introduction, suggesting

65 ease before vs after the introduction of the varicella vaccination program.

66 tes before and after the introduction of the varicella vaccination program.

67 is unlikely to be due to the introduction of varicella vaccination, antiviral therapy, or change in t

68 ing in adults 15-35 years after the start of varicella vaccination.

69 wo doses of a combined measles-mumps-rubella-varicella vaccine (MMRV), one live attenuated varicella

70 vaccine or a combined measles-mumps-rubella-varicella vaccine (MMRV).

71 aricella vaccine (MMRV), one live attenuated varicella vaccine (V) dose given after one measles-mumps

72 Efficacy of one-dose varicella vaccine against all varicella was 65.4% (57.2-

73 given as either MMR or measles-mumps-rubella-varicella vaccine and collectively referred to as MMR va

74 Humoral immune responses to varicella vaccine are best achieved when children with P

75 roup), or (2) MMR at dose one and monovalent varicella vaccine at dose two (MMR+V group), or (3) two

76 as associated with a 4.0% increase in 1-dose varicella vaccine coverage.

77 The Oka/Merck varicella vaccine induces VZV immunity in elderly nursin

78 Live attenuated varicella vaccine is recommended for healthy individuals

79 Immunisation is possible with monovalent varicella vaccine or a combined measles-mumps-rubella-va

80 a in naive children administered one dose of varicella vaccine or two doses of MMRV.

81 served, suggests that a two-dose schedule of varicella vaccine provided optimum long-term protection

82 were stratified by age: less than 20 years (varicella vaccine recommended), 20 to 59 years (no vacci

83 The live, attenuated varicella vaccine strain (vOka) is the only licensed the

84 Since the introduction of the varicella vaccine to the routine immunization schedule,

85 virus (VZV)-containing vaccine (hereafter, "varicella vaccine") in frail nursing homes residents nor

86 accine uptake for 2-dose MCV and single-dose varicella vaccine, focusing on timeliness.

87 ses of MMRV, one dose of MMR and one dose of varicella vaccine, or two doses of MMR, 42 days apart.

88 Despite no change in the scheduled age of varicella vaccine, use of MMRV vaccine was associated wi

89 ed 60-75 years (a comparison group) received varicella vaccine.

90 n immunocompromised patient who received the varicella vaccine.

91 The duration of protection provided by varicella vaccines is unclear.

92 rred partial cross-protection against simian varicella virus (SVV) challenge.

93 Simian varicella virus (SVV) infection of rhesus macaques recap

94 Since infection of rhesus macaques by simian varicella virus (SVV) is used as an animal model of VZV

95 Like varicella-zoster virus (VZV), simian varicella virus (SVV) reactivates to produce zoster.

96 l inoculation of rhesus macaques with simian varicella virus (SVV) recapitulates the hallmarks of VZV

97 Infection of rhesus macaques with simian varicella virus (SVV), a homolog of VZV, provides a robu

98 l inoculation of rhesus macaques with simian varicella virus (SVV), a homolog of VZV, recapitulates t

99 ulation of rhesus macaques (RMs) with simian varicella virus (SVV), a homolog of VZV, recapitulates v

100 ques intrabronchially inoculated with simian varicella virus (SVV), the counterpart of human varicell

101 y challenged with the closely related Simian Varicella Virus (SVV).

102 nostic test for measles, mumps, rubella, and varicella virus immunity, in this study, we have validat

103 he importance of these countermechanisms for varicella virus infection.

104 l role of CD4 T cell immunity in controlling varicella virus latency.

105 role for CD4 T cell immunity in controlling varicella virus latency.IMPORTANCE Reactivation of laten

106 ion of the host response required to control varicella virus replication in the lung and provide insi

107 ) were used to assess humoral immunity; anti-varicella virus T-cell responses were studied in a subse

108 ibodies against measles, mumps, rubella, and varicella viruses simultaneously.

109 to study how increasing the vulnerability of varicella viruses to innate immunity will impact viral p

110 cy of one-dose varicella vaccine against all varicella was 65.4% (57.2-72.1), and against moderate to

111 Efficacy of two-dose MMRV against all varicella was 94.9% (97.5% CI 92.4-96.6), and against mo

112 Vaccine efficacy against all varicella was 95.4% (95% CI 94.0-96.4) for MMRV and 67.2

113 vaccine efficacy against moderate or severe varicella was 99.1% (97.9-99.6) for MMRV and 89.5% (86.1

114 I 92.4-96.6), and against moderate to severe varicella was 99.5% (97.5-99.9).

115 rations (GMCs) to TT, PT, PCV serotypes, and varicella were lower in postchemotherapy participants th

116 events for some outcomes such as scabies or varicella, which may have led to limited statistical pow

117 of herpes zoster disease, which is caused by Varicella zoster Nevertheless, the pathophysiological me

118 megalovirus (HR, 3.98 [95% CI, 1.40-11.26]), varicella zoster virus (HR, 1.49 [95% CI, 1.18-1.89]), h

119 = 60), followed by tuberculosis (n = 8) and varicella zoster virus (n = 7).

120 Varicella zoster virus (VZV) antibody titers (measured b

121 Varicella zoster virus (VZV) antigen was found in all of

122 lex virus types 1 (HSV-1) and 2 (HSV-2), and varicella zoster virus (VZV) by weekly polymerase chain

123 Varicella zoster virus (VZV) establishes latency in dors

124 Varicella zoster virus (VZV) establishes lifelong persis

125 s positive for herpes simplex virus (HSV) or varicella zoster virus (VZV) in 79% to 100% of cases of

126 Clinical reports observe the reactivation of varicella zoster virus (VZV) in people who have recovere

127 Reactivation of the varicella zoster virus (VZV) increases during aging.

128 Varicella zoster virus (VZV) is a skin-tropic virus that

129 As) from patients with giant cell arteritis, varicella zoster virus (VZV) is seen in perineurial cell

130 Varicella zoster virus (VZV) is the causative agent of c

131 Varicella Zoster Virus (VZV) is the causative agent of v

132 s" postulates that reexposure to circulating varicella zoster virus (VZV) over the life span inhibits

133 Varicella zoster virus (VZV) typically causes chickenpox

134 te the efficacy and safety of an inactivated varicella zoster virus (VZV) vaccine for herpes zoster p

135 s, granulomatous aortitis, and intracerebral varicella zoster virus (VZV) vasculopathy.

136 lovirus (CMV), Epstein-Barr virus (EBV), and varicella zoster virus (VZV) was determined in crewmembe

137 IL-10 and immunity to varicella zoster virus (VZV) were measured at baseline a

138 cytomegalovirus, herpes simplex virus (HSV), varicella zoster virus (VZV), and rubella.

139 c primers to detect DNA from JC virus (JCV), varicella zoster virus (VZV), cytomegalovirus (CMV), Eps

140 d were hepatitis A (HAV), hepatitis B (HBV), varicella zoster virus (VZV), measles, and mumps.

141 on childhood disease, chicken pox, caused by varicella zoster virus (VZV), over an 11-y period.

142 immunogenicity of live-attenuated Oka/Merck varicella zoster virus (VZV)-containing vaccine (hereaft

143 Boost of varicella zoster virus (VZV)-specific cellular immunity

144 ses with age, which leads to reactivation of varicella zoster virus (VZV).

145 1 and 2 and the sequence-divergent pathogen varicella zoster virus (VZV).

146 ompromised individuals after reactivation of varicella zoster virus (VZV).

147 n pathogens herpes simplex viruses (HSV) and varicella zoster virus (VZV).

148 CF; human cytomegalovirus (HCMV) 11% in GCF; varicella zoster virus 6% in saliva and 3% in GCF; of hu

149 ytomegalovirus [CMV], herpes simplex I/II or varicella zoster virus [HSV/VZV], blood stream infection

150 RN, PCR-positive for herpes simplex virus or varicella zoster virus and evaluated between January 200

151 beyond CMV to other herpes viruses, such as varicella zoster virus and possibly Epstein-Barr virus.

152 ence of confirmed varicella (by detection of varicella zoster virus DNA or epidemiological link) from

153 Varicella zoster virus encephalitis was infrequent follo

154 were randomized 1:1 to receive either HZ/su (varicella zoster virus glycoprotein E; AS01B Adjuvant Sy

155 cation) were associated with protection from varicella zoster virus infection (hazard ratio, 0.43; 95

156 nd increased susceptibility to bacterial and varicella zoster virus infections.

157 One patient with varicella zoster virus meningitis and acute GVHD had iC9

158 derate quality showed an association between varicella zoster virus reactivation (ophthalmic zoster)

159 ion (PCR) for herpes simplex virus (HSV) and varicella zoster virus was done in 237 (69%) and 82 (24%

160 -Barr virus, 3%; herpes simplex virus 1, 3%; varicella zoster virus, 3%; HHV7, 2%; and herpes simplex

161 nstrate that childhood infections, including varicella zoster virus, are associated with an increased

162 for other infections (herpes simplex virus, varicella zoster virus, bacterial and fungal infections)

163 itis (AU), owing to either herpes simplex or varicella zoster virus, by using the Standardization of

164 se encephalitis virus, herpes simplex virus, varicella zoster virus, cytomegalovirus, dengue virus an

165 gnificant members of the herpesvirus family: varicella zoster virus, human cytomegalovirus, and Epste

166 genes, Treponema pallidium, parvovirus, HIV, varicella zoster virus, Rubella, Cytomegalovirus, and He

167 highly dependent on the host cell, we tested varicella zoster virus-infected cell lysates and clinica

168 nation that elicited an exceptionally strong varicella zoster virus-specific B-cell and CD8 T-cell re

169 ese is also activated by the closely related varicella zoster virus.

170 ew mutations or recombination with wild-type Varicella zoster virus.

171 2, cytomegalovirus, Epstein-Barr virus, and varicella zoster virus.

172 erpes simplex virus and 8 patients (38%) had varicella zoster virus.

173 bacterial and viral (due to herpes simplex, varicella zoster, and enteroviruses) meningitis/encephal

174 reaction (PCR) analysis for Herpes simplex, varicella zoster, cytomegalovirus, Epstein-Barr virus an

175 roidism, hypercholesterolemia, hypertension, varicella zoster, peripheral vascular disease, and autoi

176 and pneumonia, and an increase observed for varicella zoster.

177 varicella-zoster virus vaccine in preventing varicella-zoster and herpes zoster is well documented, a

178 clonal expansions in response to attenuated varicella-zoster vaccination in four pairs of adult iden

179 Two doses of live-attenuated varicella-zoster vaccine are recommended for human immun

180 thy, such as prior herpes simplex keratitis, varicella-zoster viral keratitis, the linear form of Thy

181 d 9 with herpes simplex virus (8.8%), 5 with varicella-zoster virus (4.9%), 27 with cytomegalovirus (

182 SV functioned as a monopartite NLS, while in varicella-zoster virus (VZV) activity required an adjace

183 Intraocular varicella-zoster virus (VZV) and HSV type 1 (HSV-1) infe

184 The herpesviruses varicella-zoster virus (VZV) and human cytomegalovirus (

185 herpes simpex virus 1 and 2 (HSV-1, HSV-2), varicella-zoster virus (VZV) and human herpesvirus 8 (HH

186 reactivation of herpesviruses, most commonly varicella-zoster virus (VZV) and pseudorabies virus (PRV

187 Infections with varicella-zoster virus (VZV) are associated with a range

188 Infection of human neurons in vitro with varicella-zoster virus (VZV) at a low multiplicity of in

189 Varicella-zoster virus (VZV) causes chickenpox and react

190 highly infectious, human-restricted pathogen varicella-zoster virus (VZV) causes chickenpox and shing

191 ating VZV from clinical specimens.IMPORTANCE Varicella-zoster virus (VZV) causes chickenpox and shing

192 Varicella-zoster virus (VZV) causes chickenpox upon prim

193 ies for treatment of VZV diseases.IMPORTANCE Varicella-zoster virus (VZV) causes herpes zoster, a maj

194 Varicella-zoster virus (VZV) characteristically forms mu

195 We studied a patient with varicella-zoster virus (VZV) CNS vasculopathy and as par

196 In this report, we investigated varicella-zoster virus (VZV) egress in a cell line from

197 The neurotropic herpesvirus varicella-zoster virus (VZV) establishes a lifelong late

198 Varicella-zoster virus (VZV) establishes latency in huma

199 Varicella-zoster virus (VZV) establishes lifelong neuron

200 ts had similar magnitude memory responses to varicella-zoster virus (VZV) ex vivo restimulation measu

201 tive target for antiviral therapy.IMPORTANCE Varicella-zoster virus (VZV) has infected over 90% of pe

202 Mechanisms of neuronal infection by varicella-zoster virus (VZV) have been challenging to st

203 nses in the bone marrow.IMPORTANCE Childhood varicella-zoster virus (VZV) immunization induces immune

204 sensitivity to detect antibody responses to varicella-zoster virus (VZV) in vaccinated individuals,

205 Varicella-zoster virus (VZV) induces apoptosis in human

206 Varicella-zoster virus (VZV) infection causes varicella,

207 Transcriptional changes following varicella-zoster virus (VZV) infection of cultured human

208 extensively studied the role of autophagy in varicella-zoster virus (VZV) infection, and have observe

209 ent infant with concurrent primary wild-type varicella-zoster virus (VZV) infection, in whom chickenp

210 Varicella-zoster virus (VZV) infections increasingly are

211 Varicella-zoster virus (VZV) is a common pathogen that c

212 Varicella-zoster virus (VZV) is a highly contagious agen

213 Varicella-zoster virus (VZV) is a highly neurotropic vir

214 Varicella-zoster virus (VZV) is a human neurotropic alph

215 The immediate early 62 protein (IE62) of varicella-zoster virus (VZV) is a major viral trans-acti

216 Varicella-zoster virus (VZV) is a medically important hu

217 Varicella-zoster virus (VZV) is a ubiquitous pathogen th

218 Varicella-zoster virus (VZV) is an alphaherpesvirus that

219 Varicella-zoster virus (VZV) is an alphaherpesvirus that

220 Varicella-zoster virus (VZV) is an extremely cell-associ

221 e major immediate early 62 (IE62) protein of varicella-zoster virus (VZV) is delivered to newly infec

222 Varicella-zoster virus (VZV) is highly cell associated w

223 mary infection, latency, and reactivation by varicella-zoster virus (VZV) is incompletely understood.

224 Varicella-zoster virus (VZV) is one of the most common a

225 Varicella-zoster virus (VZV) is under consideration as a

226 f herpes simplex virus 1 (HSV-1), HSV-2, and varicella-zoster virus (VZV) on 695 consecutive cutaneou

227 The varicella-zoster virus (VZV) open reading frame 54 (ORF5

228 ced syncytium formation, a characteristic of varicella-zoster virus (VZV) pathology in skin and senso

229 IMPORTANCE The neurological damage caused by varicella-zoster virus (VZV) reactivation is commonly ma

230 The varicella-zoster virus (VZV) terminase components (pORF2

231 r herpes simplex virus 1 (HSV-1), HSV-2, and varicella-zoster virus (VZV) to the BD Max system by usi

232 Studies of varicella-zoster virus (VZV) tropism for T cells support

233 Varicella-zoster virus (VZV) vaccine appears to be safe

234 Although a varicella-zoster virus (VZV) vaccine has been used for m

235 ldhood immunization with the live-attenuated varicella-zoster virus (VZV) vaccine induces protective

236 75 years) immunized with the live-attenuated varicella-zoster virus (VZV) vaccine.

237 Varicella-zoster virus (VZV) vasculopathy produces strok

238 ent of active lesions (e.g. HSV-1, HSV-2 and varicella-zoster virus (VZV)).

239 Varicella-zoster virus (VZV), a double-stranded DNA alph

240 The immediate early 62 protein (IE62) of varicella-zoster virus (VZV), a major viral trans-activa

241 Primary infection with varicella-zoster virus (VZV), a neurotropic alphaherpesv

242 Regulation of gene transcription in varicella-zoster virus (VZV), a ubiquitous human neurotr

243 ults for herpes simplex virus 1/2 (HSV-1/2), varicella-zoster virus (VZV), cytomegalovirus (CMV), or

244 icella virus (SVV), the counterpart of human varicella-zoster virus (VZV), developed primary infectio

245 In this study, quantitative PCR detected varicella-zoster virus (VZV), herpes simplex virus 1 (HS

246 ing the medically important alphaherpesvirus varicella-zoster virus (VZV), induce fusion of the virio

247 Varicella-zoster virus (VZV), of the family Alphaherpesv

248 Like varicella-zoster virus (VZV), simian varicella virus (SV

249 Thus, we examined whether varicella-zoster virus (VZV)-infected cells produce amyl

250 In varicella-zoster virus (VZV)-infected primary human brai

251 To measure varicella-zoster virus (VZV)-specific immune responses u

252 ssays and flow cytometry, we determined that varicella-zoster virus (VZV)-specific peak T helper 1 (V

253 lication that can occur with reactivation of varicella-zoster virus (VZV).

254 potency against hepatitis B virus (HBV) and varicella-zoster virus (VZV).

255 itive GCA is associated with TA infection by varicella-zoster virus (VZV).

256 Our work has shown that varicella-zoster virus (VZV; also called human herpesvir

257 None have yet been reported in varicella-zoster virus (VZV; also known as human herpesv

258 nate gene activation by live yellow-fever or varicella-zoster virus (YFV/VZV) vaccines was more suspe

259 onal and pathogen-specific stimulation (with varicella-zoster virus [VZV] and cytomegalovirus [CMV]).

260 virus 1 [HSV-1], HSV-2, JC virus [JCV], and varicella-zoster virus [VZV]).

261 y, other human-restricted viruses.IMPORTANCE Varicella-zoster virus and human cytomegalovirus infect

262 finding associated with uveitis secondary to varicella-zoster virus and Toxoplasma gondii coinfection

263 s of anterior uveitis in his left eye due to varicella-zoster virus and Toxoplasma gondii coinfection

264 Varicella-zoster virus antigen was found in 45 of 70 GCA

265 Varicella-zoster virus antigen was frequently found in p

266 e whether herpes zoster antigen (also called varicella-zoster virus antigen) was detectable in tempor

267 gical boosting, through which reexposures to varicella-zoster virus are thought to reduce the individ

268 clonal antibodies against a major antigen of varicella-zoster virus called gE.

269 MPORTANCE Herpes simplex viruses 1 and 2 and varicella-zoster virus cause significant morbidity and m

270 We compared varicella-zoster virus cell-mediated immunity (VZV-CMI)

271 ES by the corresponding region from ORF61 of varicella-zoster virus did not rescue ND10 fusion.

272 th HSE (p.Leu297Val) and 1 in a patient with varicella-zoster virus encephalitis (p.Leu199Phe).

273 the phenotypic spectrum of TLR3 mutations to varicella-zoster virus encephalitis and support the role

274 ve (at months 0, 1, 3) three doses of 50 mug varicella-zoster virus glycoprotein E (gE) adjuvanted wi

275 ubjects received 3 doses of HZ/su (50 microg varicella-zoster virus glycoprotein E [gE] combined with

276 g older adults, a subunit vaccine containing varicella-zoster virus glycoprotein E and the AS01B adju

277 zoster vaccine showed a greater increase in varicella-zoster virus gpELISA antibody compared with su

278 ogic modulators restores immune responses to varicella-zoster virus in vaccinees.

279 or who had resided in a country with endemic varicella-zoster virus infection for 30 years or more we

280 erties that may favor reactivation of latent varicella-zoster virus infection.

281 regulate infection of host cells.IMPORTANCE Varicella-zoster virus is an important human pathogen, w

282 Available varicella-zoster virus models can be classified in 3 mai

283 ilar function in human herpesviruses such as varicella-zoster virus or herpes simplex viruses.

284 -coinfected children and were independent of varicella-zoster virus or herpes-simplex virus 1 coinfec

285 The continued success of the live attenuated varicella-zoster virus vaccine in preventing varicella-z

286 The licensed live, attenuated varicella-zoster virus vaccine prevents herpes zoster in

287 ty for CMV, EBV, herpes-simplex virus 1, and varicella-zoster virus were studied in 1079 6-year-old c

288 ncing to identify nosocomial transmission of varicella-zoster virus with fatal outcome.

289 2, human herpesvirus 6, human parechovirus, varicella-zoster virus, and Cryptococcus neoformans/Cryp

290 (HSV) and other alphaherpesviruses, such as varicella-zoster virus, depend upon the capacity to navi

291 ZVL and, together with baseline immunity to varicella-zoster virus, explains the effect of age on th

292 erritin levels were highest in patients with varicella-zoster virus, hepatitis, or malaria (median, 1

293 es (parechovirus, dengue virus, Nipah virus, varicella-zoster virus, mumps virus, measles virus, lyss

294 h HLA-B27-associated (4460 [2465] pg/mL) and varicella-zoster virus-associated (5386 [1778] pg/mL) uv

295 the change from baseline in IgG antibody to varicella-zoster virus-specific glycoproteins (gpELISA)

296 losely related to herpes simplex viruses and varicella-zoster virus.

297 pathogens herpes simplex viruses 1 and 2 and varicella-zoster virus.

298 Mumps, measles, rubella, and varicella-zoster viruses (MMRV) may cause severe infecti

299 Immunity to measles, mumps, rubella, and varicella-zoster viruses (VZV; MMRV) is a common conditi

300 smosis, other infections (such as syphillis, varicella-zoster, and parvovirus B19), cytomegalovirus,